Regeneron
Regeneron makes Libtayo and has a large portfolio of CD3 bispecifics (odronextamab, linvoseltamab).
Cemiplimab, odronextamab (CD20×CD3), linvoseltamab (BCMA×CD3, approved 2025), fianlimab (LAG-3), costimulatory bispecifics.
A PD-1 blocker that is the standard for advanced skin squamous cell carcinoma, and in 2025 became the first adjuvant immunotherapy for it.
Fianlimab is Regeneron's LAG-3 blocker. Promising early data with cemiplimab did not hold up against pembrolizumab in a first-line phase 3 in 2026.
Linvoseltamab is Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study.
Odronextamab is Regeneron's CD20 bispecific, approved in Europe for lymphoma and in the US for follicular lymphoma after earlier FDA rejections over confirmatory-trial enrolment.
Pages like this
not linked directly; found by shared links- PairingCaution: LAG-3 blockade outside active disease
Shares Fianlimab, Fianlimab + cemiplimab phase 3 (first-line melanoma), Melanoma.
- InstitutionUniversity of Arizona Cancer Center
Shares Basal cell carcinoma, Cutaneous squamous cell carcinoma, Melanoma.
- CompanySanofi
Shares EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9, Basal cell carcinoma, Cutaneous squamous cell carcinoma, Multiple myeloma.
- TrialLINKER-MM1
Shares Linvoseltamab, Multiple myeloma.
- TechnologyDermoscopy, total-body photography & AI skin analysis
Shares Basal cell carcinoma, Cutaneous squamous cell carcinoma, Melanoma.
- CompanyGenmab
Shares Follicular lymphoma, Multiple myeloma, Cervical cancer, Diffuse large B-cell lymphoma.
- PairingCaution: T-cell redirectors and infections
Shares Linvoseltamab, Multiple myeloma.
- TargetLAG-3
Shares Fianlimab, Fianlimab + cemiplimab phase 3 (first-line melanoma), Melanoma.